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Abstract 
Background. 
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy 
(CRS/HIPEC) is a treatment option for selected patients with peritoneal 
carcinomatosis. There are limited data available on anaesthesia management and its 
impact on patients’ outcome. Our aim was to retrospectively analyse and evaluate 
perioperative management and clinical course of patients undergoing CRS/HIPEC 
within a three-year period. 
 
Methods. 
After ethic committee approval, patient charts were retrospectively reviewed for 
patient characteristics, interventions, perioperative management, postoperative 
course and complications. Analysis was intervention based. Data are presented as 
median (range).  
 
Results.  
Between 2009 and 2011, 54 consecutive patients underwent 57 interventions; 
median anaesthesia time was 715 (370-1135) min. HIPEC induced hyperthermia with 
overall median peak temperature of 38.1 (35.7-40.2) °C with active cooling. Median 
blood loss was 0.8 (0-6) l and large fluid shifts occurred, requiring total fluid input of 
8.4 (4.2-29.4) l per case. Postoperative renal function was dependent on 
preoperative function and type of fluids used. Administration of hydroxyethyl starch 
colloid solution had a significant negative impact on renal function, especially in 
younger patients. Major complications occurred after 12 procedures leading to death 
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in 2 patients. Procedure time and need for blood transfusion were associated with a 
significantly higher risk for major complications.  
 
Conclusions.  
Cytoreductive surgery with HIPEC is a high-risk surgical procedure associated with 
major haemodynamic and metabolic changes. Besides primary disease and 
complexity of surgery, we could show that anaesthesia management, the type and 
amount of fluids used and blood transfusions have a significant effect on patients’ 
outcome. 
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Background 
Over the last two decades, cytoreductive surgery combined with hyperthermic 
intraoperative chemotherapy (CRS/HIPEC) has become a therapeutic option for 
selected patients with peritoneal carcinomatosis [1]. Traditionally, peritoneal 
carcinomatosis was considered a palliative incurable condition [2]. Sugarbaker in 
1995, however, first described that some of these patients may benefit from surgical 
removal of all macroscopic tumour combined with locoregional chemotherapy [3]. 
Since then, CRS/HIPEC has increasingly been used to treat patients with peritoneal 
carcinomatosis of different origin [4-11]. 
Strict patient selection is crucial and meticulous surgical tumour removal is 
mandatory for best clinical outcome [9, 12-14]. Thereby, long-time survival with good 
quality of life is feasible [15]. As there is a learning curve performing CRS/HIPEC, 
centralisation of the procedure to specialized institutions is recommended [16]. 
Regarding anaesthesia management and perioperative care, experience is limited 
and consensus has to be found yet [17]. Several authors have shown major changes 
in body temperature and haemodynamics, alterations in the composition of the blood 
as well as need for massive transfusion [18-21].  
The aim of our study was to retrospectively analyse anaesthesia management and 
postoperative course of patients undergoing CRS/HIPEC over a 3-year period since 
introduction of this combined technique at the University Hospital Zurich. 
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Methods 
After ethic committee approval (KEK: 2012-0174), all patients operated in a three-
year period from 2009-2011 were included from a prospective database. Charts were 
retrospectively reviewed. There were no exclusion criteria. Fifty-four patients 
underwent 57 procedures. Data analysis was based on the number of procedures 
(57=100%). 
 
Data collection and study variables 
Anaesthesia and perioperative data were collected from electronic patient records 
(KISIM™, CISTEC AG, Zurich, Switzerland). Surgery was divided into three phases: 
CRS, HIPEC and reconstruction. Furthermore, we defined 6 particular time points in 
order to describe the course of the intervention (Figure 1). Data were collected on 
patient characteristics, anaesthesia, intraoperative fluid, transfusion and coagulation 
management, microcirculation and body temperature. Laboratory values and blood 
gas analysis were recorded until the second post-operative day. Additionally, post-
operative course including complications according to the Clavien-Dindo 
classification were recorded, major complications including re-interventions under 
general anaesthesia (grade 3b), life-threatening complications requiring ICU 
management (grade 4) and death (grade 5) [22]. 
 
Cytoreductive surgery and HIPEC 
All patients underwent extensive CRS followed by HIPEC. Peritonectomy was 
performed as described by Sugarbaker [3]. For HIPEC, the open abdomen 
technique, also referred to as the “coliseum technique”, was used, allowing the 
surgeons to manipulate abdominal content [23]. Inflow and outflow tubes were 
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connected to the hyperthermia pump (Belmont® Hyperthermia Pump, Belmont 
Instrument Corporation, Billerica, USA) and 750-1000 ml min-1 of pre-heated 1.5 % 
glucose peritoneal dialysis solution were circulated through the abdominal cavity. 
When target temperature of 41-42°C was reached, chemotherapeutic agents were 
added to the solution. Three different chemotherapeutic regimens were used: 
doxorubicin combined with either mitomycin or cisplatin and cisplatin combined with 
mitomycin. HIPEC was scheduled for 60 or 90 min; afterwards, the perfusate was 
drained and the abdominal cavity washed out with 4000 ml of normal saline (37°C). 
To prevent systemic hyperthermia, active cooling with forced air, cold packs and 
infusion of cold fluids (4°C) was used. 
 
Anaesthesia and postoperative care 
Anaesthesia was performed according to institutional guidelines with propofol or 
volatile anaesthetics with restrictive transfusion management and extensive 
haemodynamic monitoring. Combined anaesthesia including continuous thoracic 
epidural anaesthesia (TEA) was the technique of choice. After surgery, patients were 
transferred to the intensive care unit (ICU) or post-anaesthesia care unit (PACU). 
However, due to the lack of standardization at this early stage, individual 
management was up to the anaesthesiologist in care.  
 
Guidance of vasopressor and fluid therapy 
To prevent volume depletion, general fluid management included a continuous 
baseline infusion aiming at an urinary output of at least 2 ml kg-1 h-1. If necessary, 
norepinephrine was applied continously in order to keep mean arterial blood pressure 
at baseline values. Arterial blood gas analyses were drawn to monitor signs of tissue 
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hypoperfusion such as decreasing pH and base excess or increasing serum lactate 
levels. Volume trials were initiated if urinary output was not achieved or signs of 
impaired microcirculation were present. If applicable, the PiCCO system [PULSION 
Medical Systems, Munich, Germany] was used for goal-directed haemodynamic and 
fluid management. In steady state, with surgical manipulation absent, parameters of 
transpulmonary thermodilution and of pulse-contour analysis were acquired: Stroke 
volume variation of higher than 10% was inerpreted as a marker for volume 
responsiveness. Changes in cardiac output, global end-diastolic volume and 
extravascular lung water indexes were monitored and used as markers for further 
volume trials or vasopressors according to the manufacturer’s haemodynamic 
decision model (www.pulsion.com/international-english/academy/download-
center/english/picco). 
 
Statistical methods 
Data were extracted from patient records and stored in an Excel File (Microsoft Office 
2011). Descriptive statistics are presented as median and ranges for continuous 
variables and as counts for categorical variables. Intraoperative changes of body 
temperature, heart rate, mean arterial blood pressure (MAP) and central venous 
pressure (CVP) were addressed separately with mixed effects models, accounting for 
repeated observations over time, and adjusting for the potential confounders age, 
gender, and body mass index (BMI). The box-cox-transformed glomerular filtration 
rate (GFR) measured postoperatively (day 1 and 2) was modelled with multiple linear 
regression. Independent factors were preoperative GFR, blood loss, urine output and 
different intravenous fluid preparations (Supplementary data, Table S1). For binary 
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outcomes such as postoperative ventilation and major (≥3b) complications, multiple 
logistic regression models were used. Independent factors are shown in Table S2. 
Resulting effect sizes correspond to the logarithm of the odds ratios (OR). 
The fentanyl consumption per kg body mass, length of postoperative ventilation, time 
to first bowel passage and the length of stay on the ICU between the groups of 
patients with and without additional thoracic epidural anaesthesia (TEA) were 
compared with a non-parametric Wilcoxon test (Table S3). P-values < 0.05 were 
considered statistically significant. 
All statistical procedures ignored the fact that three patients had two HIPEC 
interventions, and observations were considered independent. All analyses were 
performed with R. [24] For descriptive statistics the package reporttools was used, for 
fitting the random effects models, package lme4 was used. Details of statistical 
analyses are presented as supplementary data (Table S1-3). 
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Results 
Data on patient characteristics and primary cancer are presented in Table 1. Fifty-
four patients underwent 57 interventions. Median BMI was 25 (16-41). The majority 
of patients suffered from cancer originating from the vermiform appendix. Other 
primary tumour localizations included colorectal and gastric cancer, mesothelioma, 
endometroid and ovarian cancer and cancer arising from urachus and small intestine. 
Median operation time was 550 (255-995) min and median anaesthesia time was 715 
(370-1135) min. Median time for CRS was 340 (95-790) min, for HIPEC 90 (60-115) 
min and for reconstruction 119 (40-237) min.  
 
Anaesthesia and Monitoring 
Data on intra- and perioperative parameters are presented in Table 2. Besides 
routine monitoring, advanced haemodynamic monitoring was used in 91% of all 
procedures (PiCCO [PULSION Medical Systems, Munich, Germany] n=48; 
pulmonary artery catheter [Swan-Ganz CCOmbo, Edwards Life Sciences, 
Unterschleissheim, Germany] n=3; both techniques n=1). General anaesthesia was 
performed according to institutional standards, 79% (n=45) were combined with a 
continuous thoracic epidural anaesthesia (TEA, ropivacaine 0.33% 6-12 ml h-1). 
Anaesthesia was maintained with propofol (n=37), sevoflurane (n=17) or desflurane 
(n=3) and supplemented with intravenous fentanyl according to patients’ needs. 
Overall median fentanyl consumption was 1.2 (range 0.2-4.0) mg. Postoperatively, 
thoracic epidural anaesthesia was maintained with ropivacaine 0.2% at a rate of 6-15 
ml h-1.  
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Body temperature and haemodynamics 
HIPEC induced hyperthermia with median overall peak temperature of 38.1 (35.7-
40.2) °C. Body temperature changed significantly over time (Figure 2A).  
The following haemodynamic changes were found (data not shown): Heart rate 
significantly increased throughout the procedure, peaking at the end of HIPEC, and 
remained high until the end of surgery. Mean arterial blood pressure was kept within 
10% of baseline. Norepinephrine was administered in 55 patients with median overall 
peak doses of 7 (0.5-30) µg min-1. Median central venous pressure (CVP) increased 
significantly during the first part of the operation (H0-H2). 
 
Fluid and coagulation management 
Detailed information on intraoperative fluid, transfusion and coagulation management 
is shown in Table 3. Coagulation parameters were analysed using routine laboratory 
testing and bedside thromboelastography (ROTEM®, Tem Innovations GmbH, 
Munich, Germany). One patient suffering from a known hereditary factor VII 
deficiency required recombinant factor VIIa. Postoperatively, 7 patients showed 
thrombocytopenia (<50000 µl-1) and 9 patients developed leukocytopenia (<4000 µl-1) 
on median postoperative day 3 (0-12). Pre-operative hemoglobin values were 127 
(97-164) g l-1, falling to a minimum of 82 (46-125) g l-1 intraoperatively. At the end of 
surgery, median haemoglobin level was 92 (range 59-128) g l-1 and remained low 
until postoperative day 2. 
 
Renal function and metabolic alterations 
Details on urine output are summarised in Table 3. To maintain urine output during 
HIPEC, fluids in combination with IV diuretics were given in 35 patients (61%). 
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Furosemide was administered in 25 patients (44%), mannitol was given in 20 
patients (35%) and 10 patients (18%) received both drugs. Median doses were 10 
(2.5-20) mg for furosemide and 20 (20-40) g for mannitol. Two patients became 
oliguric (urine output < 0.5 ml kg-1 h-1) without clinical relevance. Preoperative 
glomerular filtration rate (GFR) had an impact on postoperative GFR: The higher the 
pre-operative value, the higher the post-operative value (p<0.001) (Table S1). 
Intraoperative blood loss and urine output had no significant impact on postoperative 
GFR (Table S1). Regarding the type of fluid administered, we did not find any 
negative effects of crystalloids on renal function. However, the amount of hydroxyl-
ethyl starch (HES) given had a significant negative effect on postoperative GFR in 
patients younger than 60 years (p<0.001) (Table S1). Three patients (5%) suffered 
from acute deterioration of renal function during their hospital stay.  
During surgery, pH and base excess (BE) decreased significantly. Lowest values 
were reached at the end of HIPEC (H3) with median pH of 7.38 (7.27-7.53) and 
median BE of -4.3 (-10.8-0.6) mEql l-1. Figure 2B describes plasma lactate levels 
inversely increasing throughout the intervention. Hyperglycaemia, defined as a blood 
glucose level of > 10 mmol l-1, was present in 42 patients (74%). Sixteen patients 
(28%) required insulin therapy intraoperatively, only one of the patients was a known 
diabetic.  
 
Post-operative course 
Median hospital stay was 17 (9-259) days and median length of ICU stay was 2 (1-
35) days. Thirty-three ICU patients were ventilated on ICU arrival. The more opioids 
given intraoperatively, the higher was the probability for postoperative mechanical 
ventilation (p<0.05, Table S2). The overall duration of surgery (p<0.001, Figure 3A) 
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and the amount of blood loss (p<0.05, Figure 3B) had a significant impact on the 
need for mechanical respiratory support (Table S2). Comparing post-operative 
course of patients with and without TEA, we found a significant difference in the 
amount of fentanyl given: Patients with combined anaesthesia needed less fentanyl 
(p<0.001). We could not show any difference in the length of post-operative 
ventilation (p=0.56), length of stay on the ICU (p=0.52) nor time to first bowel 
passage (p=0.73) between the two groups (Table S3). However, the sample was 
strongly unbalanced, as sample sizes in the two groups were very different and data 
were missing. Regarding anaesthesia-related complications, one patient developed 
an epidural abscess after TEA, requiring operative decompression 7 days after 
insertion. 
 
Major surgical complications (≥3b) 
Major complications according to the Clavien-Dindo classification (grade 3b-5) [22] 
occurred after 12 interventions, two patients (4%) died. The first patient, a 46-year 
old man, was suffering from adenocarcinoma of the oesophagogastric junction and 
underwent transhiatal oesophagogastrectomy. Effective operation time was 800 min. 
The patient required 8 units of PRBC, 500 IU prothrombine complex concentrate 
(PCC) and 10 g fibrinogen due to extensive bleeding (lowest haemoglobin 47 g l-1) 
intraoperatively. After an uneventful initial recovery, the patient died 17 days later 
from haemorrhagic shock and multiorgan dysfunction syndrome. The second patient, 
a 57-year old man, was suffering from a mucinous adenocarcinoma of the appendix 
with peritoneal carcinomatosis. Effective operation time was 995 min. Surgery was 
complex and the patient required 4 units of PRBC (lowest haemoglobin 71 g l-1), one 
unit of platelets and several coagulation factor concentrates (14 g fibrinogen, 2500 IU 
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factor XIII, 1000 IU PCC and 1000 IU factor VIII). After a long postoperative course 
with several re-interventions the patient died after 259 days from septic shock. 
The rate of major surgical complications increased significantly with longer operation 
(Figure 3C) and anaesthesia time (both p<0.01; Figure 3D, Table S2). We found 
blood transfusion to be an independent risk factor for major complications (p<0.05; 
Table S2). The lowest overall haemoglobin values (describing the amount of blood 
loss) correlated with a trend towards an increased risk of major complications 
(p=0.05, Table S2). The administration of coagulation factor concentrates did not 
increase the risk of major complications nor did the presence of obesity, arterial 
hypertension, carcinoma of the appendix or pre-operative anaemia (Table S2).  
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Discussion 
Data on anaesthesia management and outcome of 57 consecutive patients 
undergoing combined CRS/HIPEC were retrospectively collected and analysed at 
our hospital. Besides the surgical complexity of the individual case, we could show 
that several factors affect patients’ outcome, i.e. type and amount of resuscitation 
fluids used, as well as blood transfusions. 
Cytoreductive surgery with HIPEC is a long-lasting, abdominal surgical procedure 
(median anaesthesia time 715 min) with additional hyperthermia and intraoperative 
chemotherapy. Extensive bleeding and fluid shifts may occur. Therefore, fluid status 
and cardiac function were continuously assessed with advanced haemodynamic 
monitoring in most of our patients.  
Currently the type and amount of fluid administration are subject of debate [25-27]. 
Our fluid management consisted of both, crystalloids and colloids: Besides 
crystalloids, 51 patients received gelatine and 14 were given HES additionally, in a 
ratio of approximately 2.5:1. At the time of observation, studies on potential harmful 
effects of HES preparations in septic ICU patients had not been published so far [28, 
29]. Our data are in accordance with these publications: HES administration had a 
significant negative impact on renal function, especially in younger patients.  
Maintaining renal function and prevention of injury is critical for best perioperative 
outcome [30]. Known risk factors for acute renal injury are hypovolaemia, 
hypotension, major surgery, nephrotoxic drugs, blood transfusions and systemic 
inflammation [31]. Haemodynamic optimisation (i.e. optimising cardiac output, tissue 
perfusion and oxygenation) is highly recommended to prevent renal injury: The goal 
is to maintain the effective circulating blood volume by careful fluid and transfusion 
management, vasopressors and inotropics [32]. Most authors recommend liberal fluid 
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regimens [14, 18, 33]. Our patients received approximately 10 ml kg-1 hr-1 of fluids 
and lost 3 ml kg-1 hr-1 (Table 3). The amount of fluids given was guided by 
haemodynamic parameters, blood gas analyses and urinary output. Most patients 
were given vasopressors to maintain MAP and, although the benefit of its application 
is questionable, 35 patients were given IV diuretics to force diuresis during HIPEC 
[32]. In fact, there is no evidence for a single pharmacological intervention during 
surgery to protect the kidneys from damage [30, 34]. 
Our data suggest that the need for blood transfusion is associated with an increased 
risk for major complications (grade ≥3b according to Clavien-Dindo score [22]). The 
amount of bleeding showed a trend towards major complications (p=0.05). It is 
standard procedure for both, the surgical and the anaesthesia team, to assess and 
estimate blood loss at the end of surgery. However, differences between both 
estimates result in inconsistent documentation. Alternatively, the decrease in 
haemoglobin concentration can be used as an indicator for blood loss: Both methods 
are widely used in clinic but are known to be of limited accuracy tending to 
underestimate actual blood loss [35]. For future studies it might be useful to refer to a 
superior, validated blood loss score taking into account the haemoglobin 
concentration of suction fluid [35].  
Exposure to blood transfusions is associated with increased morbidity and mortality 
in surgical oncology [36, 37]. It is therefore critical to control surgical bleeding and to 
diagnose and correct coagulopathy early. Goal-directed, aggressive treatment using 
algorithms and point-of-care coagulation testing is recommended [36]. In our study, 
28% of patients required intraoperative blood transfusions and 37% of patients were 
given coagulation factor concentrates. In contrast to others, routine FFP 
administration is not the first-line treatment for established coagulopathy at our 
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institution [17]. Only 5% of patients received FFPs compared to 45% described in the 
literature [17, 18]. The pathophysiology of coagulopathy in patients undergoing 
CRS/HIPEC is not completely understood [14, 17]. Besides bleeding, consumption 
and dilution, patients are exposed to extreme changes in body temperature, both 
hypo- and hyperthermia, suffer from metabolic acidosis and calcium depletion (40% 
of our patients required calcium supplementation).  
The use of TEA is recommended for patients undergoing CRS/HIPEC to provide 
optimal pain therapy, to reduce length of postoperative ventilation and pulmonary 
complications and to allow early mobilisation [14, 33]. Critics underline the potential 
risk of haemodynamic instability, epidural haematoma and infectious complications 
due to massive bleeding, impaired coagulation and chemotherapy-induced 
immunodeficiency [38-40]. Recently an incidence for infectious complications of 
1:2139 has been reported [17]. One of our patients suffered from epidural abscess 
with need for operative decompression 7 days after placement. To prevent infections 
we recommend to limit the postoperative use of epidural analgesia to a maximum of 
5 days and to daily visit patients with TEA. Despite the frequent use of TEA, only 28 
% of CRS/HIPEC centres describe their pain management as excellent [17]. Most of 
our patients received TEA for intra- and post-operative analgesia and we found a 
significant opiod sparing effect. However, unlike previous publications, we could not 
show that TEA was associated with reduced length of post-operative ventilation and 
ICU-stay, nor shortened time to first bowel passage [18]. 
The present observational study has some limitations. The anaesthesia management 
of patients did not follow strict protocols and there were no pre-defined exclusion 
criteria to the study. Furthermore data were collected retrospectively and some data 
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were missing due to absent documentation, compromising data analysis and 
reducing power of statistical conclusions. 
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Conclusion 
Taken together, combined CRS/HIPEC is a high-risk surgical procedure associated 
with major haemodynamic and metabolic changes. It requires coordinated and 
patient-centred anaesthetic management, including meticulous monitoring of the 
different physiological systems of the body. Besides primary disease and complexity 
of surgery, we could show that the type and amount of fluids used, transfusions and 
anaesthetic management have an impact on patients’ outcome. To further 
differentiate factors affecting the outcome prospective, randomized, controlled trials 
are highly warranted in this field.  
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Table 1: Patient characteristics, primary cancer and intraperitoneal chemotherapy 
Age; years 52 (20-72) 
Gender; M:F 23:34 
Weight; kg / Height; cm 70 (44-112) / 168 (155-185) 
Body Mass Index; kg m-2 25 (16-41) 
ASA class I/II/III 5/49/3 
Co-Morbidities 1 
Cardiovascular 
Pulmonary 
Renal 
Endocrine 
Neurological 
Obesity (BMI>30) 
 
14 
5 
4 
3 
4 
8 
Medication 
Single ß-blocking agent 
Single ACE-Inhibitor/AT1-Blocker 
Single diuretic 
Combination of at least two drugs 
Other drugs2 
None 
Origin of primary cancer  
Appendix 
Ovary 
Colorectal 
Mesothelioma 
Gastric 
Other origin3 
 
2 
3 
0 
6 
27 
23 
 
33 
1 
13 
5 
1 
4 
 
54 patients underwent 57 procedures. Data are expressed as median (range) and 
numbers. 
ASA=American Society of Anesthesiology, BMI= body mass index (kg m-2), 
ACE=angiotensin converting enzyme, AT=angiotensin  
1 Co-morbidities: cardiovascular (arterial hypertension, cardiac valve pathology, 
hyperlipidaemia); pulmonary (chronic bronchitis, asthma, obstructive sleep apnoe 
syndrome, history of acute respiratory distress syndrome, history of pulmonary 
embolism); renal (one sided kidney agenesia, history of carcinoma of the kidney, 
incidentaloma, chronic kidney disease); endocrine (previous ovarectomy, medically 
28 
treated hypothyroidism, diabetes mellitus); neurological (polyneuropathy, 
paraesthesia, migraine, herniated vertebral disc with neurological symptoms). 
2 Twenty seven patients were on additional medication: analgesics (n=9), proton 
pump inhibitors (n=6), vitamins and supplements (n=5), laxatives (n=5), hormone 
replacement therapy (n=5), sedatives (n=3), oral antidiabetics (n=1), 
chemotherapeutic agents (n=1), antidepressants (n=1), antidiarrheals (n=1), 
antiemetics (n=1), ASS (n=1), statins (n=1), calcium channel blocker (n=1), herbal 
and homeopathic preparations (n=2). 
3 Other origin summarizes endometroid cancer (n=2), cancer of the small intestine 
(n=1) and urachus cancer (n=1). 
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Table 2: Intra- and perioperative parameters 
Anaesthesia time; min 715 (370-1135) 
Additional thoracic epidural 
anaesthesia 
45 
Advanced haemodynamic monitoring 
PiCCO 
Pulmonary artery catheter 
both 
 
48 
3 
1 
Anaesthesia maintainance 
Propofol 
Sevoflurane 
Desflurane 
 
37 
17 
3 
Cumulative fentanyl dose; mg 1.2 (0.2-4.0) 
Effective operation time; min 
Length of CRS; min 
Length of HIPEC, min 
Length of reconstruction; min 
550 (255-995) 
340 (95-790) 
90 (60-115) 
119 (40-237) 
Intraperitoneal chemotherapy (mg m-2) 
Doxorubicin/Mitomycin (15/15) 
Doxorubicin/Cisplatin (15/50) 
Cisplatin/Mitomycin (17/10)1 
 
49 
6 
2 
Transfer to ICU 53 
Length of ICU stay; d 2 (1-35) 
Postoperative ventilation 33 
Length of postoperative ventilation; 
hours2 
4 (1-10) 
Hospital stay; d 17 (9-259) 
 
Data presented as median (range) or numbers (n). 
CRS = Cytoreductive surgery, HIPEC = hyperthermic intraperitoneal chemotherapy, 
ICU = Intensive care unit 
Haemodynamic monitoring: PiCCO [PULSION Medical Systems, Munich, Germany]; 
Pulmonary artery catheter [Swan-Ganz CCOmbo, Edwards Life Sciences, 
Unterschleissheim, Germany] 
1 Reduced dose of cisplatin was given in n = 2 patients. 
2 Data missing in n = 6 patients 
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Table 3: Perioperative fluid balance, blood loss and substitution 
 n Median (range) 
Input 
 
Fluids 
Crystalloids; ml 
Crystalloids per hour; ml h-1 
Colloids; ml 
Colloids per hour; ml h-1 
HES 130/0.4; ml 
Gelatine; ml 
 
Blood products  
and coagulation factor concentrates 
PRBC; n 
FFP; n 
Thrombocytes; n 
Fibrinogen; g 
Prothrombine Complex Concentrate; IE 
Factor XIII; IE 
Factor VIII-vWF; IE 
Recombinant Factor VII; µg 
 
Total input; ml 
Total hourly input; ml h-1 
 
Output 
Blood loss; ml 
Urine; ml 
Urine per hour, CRS; ml h-1 
Urine per hour, HIPEC; ml h-1 
Urine per hour, Reconstruction; ml h-1 
Ascites; ml 
 
Total output; ml 
Total hourly output; ml h-1 
 
 
 
57 
 
56 
 
14 
51 
 
 
 
16 
3 
4 
21 
9 
13 
1 
1 
 
57 
 
 
 
57 
57 
 
 
 
11* 
 
57 
 
 
 
 
5900 (2200-19100) 
473 (187-1041) 
2500 (500-14500) 
189 (52-852) 
1000 (500-2500) 
2500 (500-12000) 
 
 
 
4 (1-10) 
6 (4-8) 
1 (1-2) 
4 (2-22) 
1000 (400-2000) 
1500 (1250-4000) 
1000 
1000 
 
8200 (4200-29400) 
697 (363-1603) 
 
 
800 (0-6000) 
1460 (330-3970) 
94 (34 -350) 
220 (47-787) 
183 (33-631) 
1500 (100-3000) 
 
2670 (530-10780) 
218 (58-729) 
 
54 patients underwent 57 procedures. Data are expressed as median (range) and 
numbers (n). 
HES = hydroxyethyl starch, PRBC = packed red blood cells, FFP = fresh frozen 
plasma, vWF = von Willebrand factor 
Fluids: Crystalloids = Ringerfundin® (B.Braun Medical AG, Melsungen, Germany); 
Colloids = gelatine (Physiogel® balanced, B. Braun Medical AG, Melsungen, 
31 
Germany) and HES 130/0.4 (Tetraspan®, B. Braun Medical AG, Melsungen, 
Germany). PRBC and thrombocytes were applied in units of 300 ml, FFP in units of 
280 ml. 
Coagulation factor concentrates: Fibrinogen (Hemocomplettan P®, CSL Behring 
AG, Bern, Switzerland), Prothrombin complex concentrate (PCC, Beriplex P/N®, CSL 
Behring AG, Bern, Switzerland), Factor XIII (Fibrogammin P®, CSL Behring AG, 
Bern, Switzerland), Factor VIII-vWF (Hemate P®, CSL Behring AG, Bern, 
Switzerland), recombinant Factor VIIa (Novoseven®, Novo Nordisk Pharma AG, 
Kusnacht, Switzerland). 
*data missing in 46 patients 
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Figure legends 
 
Figure 1: Time course of procedure.  
HIPEC = hyperthermic intraperitoneal chemotherapy, baseline = after induction of 
anaesthesia but 5 minutes before start of the operation, H0 = 30 min before HIPEC, 
H1 and H2 = 30 and 60 min after start of HIPEC, H3 = end of HIPEC, End = 5 
minutes before end of the operation. 
 
Figure 2: Intraoperative course of temperature and lactate. 
A. Change in temperature compared to baseline: the horizontal line set at 0 is 
representing baseline. If the 95% confidence interval presented for each time point 
does not overlap with baseline, temperature differs significantly from baseline 
(p<0.05). A mixed effect model describing the effect of phase was used. 
B. Boxplot describing arterial lactate levels throughout the intervention 
Baseline = after induction of anaesthesia but before start of the operation, H0 = 30 
minutes before HIPEC, H1 and H2 = 30 and 60 minutes after start of HIPEC, H3 = 
end of HIPEC, End = 5 minutes before end of the operation. 
 
Figure 3: Operation time, blood loss and anaesthesia time and their effects on 
the need for post-operative ventilation and major surgical complications. 
A and B. The multiple logistic regression model describes the need for postoperative 
respiratory assistance (vertical axis: 0 = no assistance, 1 = assistance needed) 
depending on operation time (minutes) and blood loss (ml). The longer the operation 
33 
(p<0.01) and the higher the blood loss (p<0.05), the higher was the need for 
postoperative ventilation.  
C and D. Major complications (≥ 3b according to the Clavien-Dindo-classification; for 
details please refer to the text) on the vertical axis (0 for complications < 3b, 1 for ≥ 
3b) are plotted against operation time (minutes) or anaesthesia time (minutes) on the 
horizontal axis. The longer the operation (p<0.01) and the longer anaesthesia time 
(p<0.01), the higher was the incidence of major complication.  
Data are corrected for BMI and age. 
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Table S 1: Multiple linear regression models 
Multiple linear regression model 
Dependent 
variable 
Independent variable Effect 
size 
Standard 
error 
p-
value 
GFR postoperative 
day 1* 
Preoperative GFR  0.729 0.154 <0.0011 
 Age -0.118 0.255 0.645 
 BMI -0.204 0.455 0.656 
GFR postoperative 
day 2* 
Preoperative GFR  0.809 0.155 <0.0011 
 Age 0.198 0.257 0.445 
 BMI -0.184 0.459 0.69 
GFR postoperative 
day 1* 
Intraoperative blood loss  -0.001 0.002 0.75 
 Age 
 
-0.131 0.26 0.618 
 BMI -0.202 0.459 0.663 
 Preoperative GFR 0.725 0.155 <0.0011 
GFR postoperative 
day 2* 
Intraoperative blood loss <-0.001 0.002 0.884 
 Age 0.192 0.267 0.468 
 BMI -0.183 0.463 0.695 
 Preoperative GFR 0.807 0.157 <0.0011 
GFR postoperative 
day 1* 
Intraoperative urine 
secretion per time 
-1.547 2.454 0.531 
 Age -0.128 0.257 0.620 
 BMI -0.214 0.458 0.643 
 Preoperative GFR 0.732 0.155 <0.0011 
GFR postoperative 
day 2* 
Intraoperative urine 
secretion per time 
1.254 2.477 0.615 
37 
 Age 0.206 0.26 0.431 
 BMI 
 
-0.176 0.462 0.705 
 Preoperative GFR 0.806 0.156 <0.0011 
GFR postoperative 
day 1* 
Amount of cristalloids given 
over time (ml min-1) 
-0.014 0.715 0.984 
 Age -0.118 0.258 0.649 
 BMI -0.204 0.46 0.659 
 Preoperative GFR 0.729 0.155 <0.0011 
GFR postoperative 
day 2* 
Amount of cristalloids given 
over time (ml min-1) 
-0.768 0.713 0.286 
 Age 0.175 0.258 0.499 
 BMI -0.187 0.458 0.685 
 Preoperative GFR 0.813 0.155 <0.0011 
GFR postoperative 
day 1* 
Age*amount of HES given 
over time (ml min-1) 
0.949 0.204 <0.0011 
 Age -0.56 0.236 0.0221 
 BMI -0.411 0.39 0.297 
 Preoperative GFR 0.805 0.132 <0.0011 
 Amount of HES given over 
time 
-52.54 11.124 <0.0011 
GFR postoperative 
day 2* 
Age*amount of HES given 
over time (ml min-1) 
0.95 0.204 <0.0011 
 Age -0.245 0.236 0.305 
 BMI -0.375 0.39 0.341 
 Preoperative GFR 0.882 0.132 <0.0011 
 Amount of HES given over 
time 
-53.906 11.116 <0.0011 
Amount of 
transfused PRBC 
Preoperative anemia 
(Hb<117g l-1) 
-0.096 0.448 0.832 
 Age -0.001 0.015 0.956 
 BMI 0.012 0.031 0.7 
38 
 
 
GFR = Glomerular filtration rate, BMI = body mass index (kg m-2), HES = 
hydroxyethyl starch, PRBC = packed red blood cells 
1Statistically significant 
*box-cox-transformed 
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Table S2: Multiple logistic regression models 
Multiple logistic regression model 
Dependent 
variable 
Independent variable Effect 
size 
Standard 
error 
p-
value 
Postoperative 
ventilation 
Amount of opiods (mg) 0.919 0.391 0.0181 
 Age 0.016 0.028 0.576 
 BMI -0.006 0.06 0.925 
Postoperatve 
ventilation 
Overall duration of operation 
(min) 
0.014 0.004 <0.0011 
 Age 0.043 0.043 0.316 
 BMI 0.015 0.076 0.84 
Postoperative 
ventilation 
Blood loss (ml) 0.002 0.001 0.0031 
 Age 0.008 0.029 0.782 
 BMI 0.02 0.064 0.749 
Complications ≥ 
3b 
Operation time (min) 0.006 0.002 0.0041 
 Age -0.03 0.042 0.48 
 BMI -0.075 0.087 0.391 
Complications ≥ 
3b 
Anaesthesia time (min) 0.006 0.002 0.0051 
 Age -0.031 0.042 0.46 
 BMI -0.077 0.087 0.379 
Complications ≥ 
3b 
Lowest intraoperative 
haemoglobin value (g l-1) 
-0.037 0.019 0.054 
 Age -0.048 0.034 0.157 
 BMI -0.052 0.08 0.515 
Complications ≥ 
3b 
Blood transfusion (0/1) 1.76 0.724 0.0151 
40 
 Age -0.038 0.034 0.268 
 BMI -0.075 0.082 0.359 
Complications ≥ 
3b 
Coagulation factor (0/1) 1.159 0.69 0.093 
 Age -0.044 0.034 0.192 
 BMI -0.066 0.081 0.414 
Complications ≥ 
3b 
Obesity  (BMI>30 kg m-2)  0.128 1.6 0.936 
 Age -0.042 0.032 0.188 
 BMI -0.072 0.106 0.501 
Complications ≥ 
3b 
Hypertension  0.778 1.082 0.472 
 Age -0.049 0.034 0.148 
 BMI -0.094 0.089 0.29 
Complications ≥ 
3b 
Carcinoma of the appendix 0.1 0.685 0.886 
 Age -0.042 0.032 0.186 
 BMI -0.067 0.077 0.38 
Complications ≥ 
3b 
Pre-operative anaemia  
(Hb<117g l-1) 
1.19 0.872 0.173 
 Age -0.048 0.032 0.129 
 BMI -0.08 0.078 0.313 
 
1Statistically significant 
BMI = body mass index (kg m-2), Hb = haemoglobin concentration (g l-1) 
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Table S 3: Wilcoxon rank sum tests 
Wilcoxon rank sum tests 
Dependent variable Groups N Mean p-
value 
Fentanyl given 
intraoperatively (mg) 
n=57 
Additional TEA 
versus no 
additional TEA  
n=45  
versus 
n=12 
0.015 versus 
0.03471854 
<0.0011 
Length of postoperative 
ventilation (h) 
in n=27** patients 
Additional TEA 
versus no 
additional TEA 
n=20  
versus 
n=7 
5.013 
versus 
4.536 hours 
0.560 
Total stay on ICU 
(days) in n=53 patients 
Additional TEA 
versus no 
additional TEA 
n=42 
versus 
n=11 
3.024 
versus 1.545 
days 
0.519 
Time to first bowel 
passage (days) 
in n=55 patients*** 
Additional TEA 
versus no 
additional TEA 
N=44 
versus 
n=11 
5.3409 versus 
5.7272 days  
0.732 
 
1Statistically significant 
**data missing in n=6 patients 
*** data missing in n=2 patients 
TEA = thoracic epidural anaesthesia, ICU = intensive care unit 
 
 
